AVE — Avecho Biotechnology Income Statement
0.000.00%
Last trade - 00:00
- AU$12.68m
- AU$7.35m
- AU$0.47m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4.24 | 0.385 | 0.794 | 1.13 | 0.474 |
Cost of Revenue | |||||
Gross Profit | 4.02 | 0.241 | 0.508 | 0.793 | -0.044 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3.39 | 3.02 | 4.21 | 3.47 | 3.91 |
Operating Profit | 0.85 | -2.63 | -3.42 | -2.34 | -3.44 |
Net Income Before Taxes | 0.85 | -2.63 | -3.42 | -2.34 | -3.44 |
Provision for Income Taxes | |||||
Net Income After Taxes | 0.85 | -2.63 | -3.42 | -2.34 | -3.44 |
Net Income Before Extraordinary Items | |||||
Net Income | 0.85 | -2.63 | -3.42 | -2.34 | -3.44 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 0.85 | -2.63 | -3.42 | -2.34 | -3.44 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.001 | -0.002 | -0.002 | -0.001 | -0.002 |